Senores Pharmaceuticals Ltd. (IN:SENORES)
:SENORES
Want to see IN:SENORES full AI Analyst Report?
SENORES Stock Chart & Stats
₹716.90
--
Market closed
₹716.90
--
Day’s Range― - ―
52-Week Range₹507.00 - ₹1,295.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)11.47K
Market Cap
₹59.47B
Enterprise Value₹54.57B
Total Cash (Recent Filing)₹3.60B
Total Debt (Recent Filing)₹2.41B
Price to Earnings (P/E)44.4
Beta1.09
Next Earnings
Jul 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.54
Shares Outstanding46,053,590
10 Day Avg. Volume13,254
30 Day Avg. Volume11,469
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.63
Price to Sales (P/S)5.35
P/FCF Ratio-16.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)33.7
Revenue Forecast (FY)₹8.28B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthA ~151% revenue increase in FY2026 reflects meaningful scale expansion and market traction. Sustained top-line growth over several quarters can enable operating leverage, support R&D and commercialization, and strengthen competitive positioning over the next 2–6 months.
Robust Profit MarginsHigh gross and operating margins indicate structural profitability potential and pricing or cost advantages. If maintained, these margins support cash generation capacity, reinvestment for growth, and margin-based resilience versus peers across medium-term business cycles.
Improving Leverage ProfileA falling debt-to-equity ratio and rising equity suggest gradual balance-sheet strengthening. This trend enhances financial flexibility for capex or partnerships, lowers refinancing stress, and supports creditworthiness over the coming months if sustained.
Bears Say
Deep Negative Free Cash FlowPersistent, large negative free cash flow implies the business is consuming cash despite reported profits. Over the medium term this pressures liquidity, may require external financing, and constrains the firm's ability to self-fund growth or reduce leverage.
Weak Earnings-to-Cash ConversionLow operating cash flow versus reported profits indicates earnings quality issues or working-capital drain. Poor conversion raises risk that reported profitability is not sustainable and can impair debt servicing, dividend ability, and reinvestment over months ahead.
Data Quality / FY2025 InconsistencyA material FY2025 balance-sheet inconsistency reduces confidence in trend analysis and may mask risks. Uncertain historical accounting or reporting anomalies complicate forecasting and increase the chance of unforeseen liabilities or restatements affecting strategic decisions.
Senores Pharmaceuticals Ltd. News
SENORES FAQ
What was Senores Pharmaceuticals Ltd.’s price range in the past 12 months?
Senores Pharmaceuticals Ltd. lowest stock price was ₹507.00 and its highest was ₹1295.00 in the past 12 months.
What is Senores Pharmaceuticals Ltd.’s market cap?
Senores Pharmaceuticals Ltd.’s market cap is ₹59.47B.
When is Senores Pharmaceuticals Ltd.’s upcoming earnings report date?
Senores Pharmaceuticals Ltd.’s upcoming earnings report date is Jul 29, 2026 which is in 45 days.
How were Senores Pharmaceuticals Ltd.’s earnings last quarter?
Senores Pharmaceuticals Ltd. released its earnings results on May 14, 2026. The company reported ₹6.9 earnings per share for the quarter, beating the consensus estimate of ₹6.29 by ₹0.61.
Is Senores Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Senores Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Senores Pharmaceuticals Ltd. pay dividends?
Senores Pharmaceuticals Ltd. does not currently pay dividends.
What is Senores Pharmaceuticals Ltd.’s EPS estimate?
Senores Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senores Pharmaceuticals Ltd. have?
Senores Pharmaceuticals Ltd. has 46,053,590 shares outstanding.
What happened to Senores Pharmaceuticals Ltd.’s price movement after its last earnings report?
Senores Pharmaceuticals Ltd. reported an EPS of ₹6.9 in its last earnings report, beating expectations of ₹6.29. Following the earnings report the stock price went down -2.282%.
Which hedge fund is a major shareholder of Senores Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:SENORES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senores Pharmaceuticals Ltd.
Established in 2017 and headquartered in Ahmedabad, India, Senores Pharmaceuticals Ltd. is actively involved in the development, manufacturing, and global commercialization of pharmaceutical and related products. Its extensive portfolio reaches markets across India, the United States, the United Kingdom, Canada, and other international territories. The company specializes in a diverse array of therapeutic solutions, encompassing analgesics/antipyretics, anesthetics, antibacterials, antivirals, antifungals, antioxidants, antineoplastics, blood-related therapies, cardiovascular and neurological medications, antacids, and vitamin and mineral supplements. Additionally, Senores offers a selection of generic drugs targeting pain, inflammation, fever, diabetes, malaria, and urinary tract conditions, as well as neutral supplements. Complementing its product offerings, the firm also provides management and consultancy services.
Technical Analysis
Balaxi Pharmaceuticals Limited
―
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Lasa Supergenerics Ltd.
―
Sakar Healthcare Ltd
―